Open access publisher BioMed Central has announced the launch of the Journal of Therapeutic Ultrasound in partnership with the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound.
Focused ultrasound has the potential to be an alternative or complement for radiation therapy, the means to dissolve blood clots, and a way to deliver drugs in extremely high concentrations to a precise point in the body, according to a press release. Therapeutic ultrasound can be used to treat cancer, uterine fibroids, essential tremor, Parkinson’s disease, epilepsy, and neuropathic pain.
“Focused ultrasound technology has enormous potential to improve the quality of lives for millions around the world,” noted Neal F Kassell, chairman and founder of the Focused Ultrasound Foundation. “The research reported in the Journal of Therapeutic Ultrasound will be central to advancing the field and will help accelerate the progress of focused ultrasound towards clinical adoption.”
The Journal of Therapeutic Ultrasound is intended to encompass all aspects of therapeutic ultrasound, such as the stimulus, inhibition, or modification of tissue function or structure via insonification. The journal will be led by editors-in-chief Arik Hananel, Focused Ultrasound Foundation, USA, and Robert Muratore, Quantum Now LLC, USA.
Deborah Kahn, BioMed Central’s publishing director said: “We’re very pleased to welcome the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound as new publishing partners to BioMed Central, and we share their excitement in launching the Journal of Therapeutic Ultrasound within our growing list of society journals.”
The launch edition included two research articles. The first looked at the impact of vaporised nanoemulsions on ultrasound-mediated ablation. An editorial on ’The Journal of Therapeutic Ultrasound—broadening knowledge in a rapidly growing field’ by editors-in-chief Arik Hananel and Robert Muratore, was also featured.
